Patients who do not achieve a complete response or relapse after initial therapy have a uniformly poor prognosis. Although second remissions are possible, the majority of the patients have only partial and short-term responses.6-" CEPP(B) is a novel, well-tolerated and effective second-line therapy for those patients who have relapsed after more aggressive doxorubicin-containing regimens. CEPP(B) has also been used as initial therapy for selected patients who could not tolerate doxorubicin.
who received CEPP(B) as first line therapy (64%). Myelosuppression was the major side effect of treatment, resulting in eight neutropenic-febrile episodes from a total of 253 courses. A single fatal toxic event occurred on a patient who developed adult respiratory distress syndrome. Overall, CEPP(B) was well-tolerated and proved to be effective palliative therapy for patients with non-Hodgkin's lymphoma after relapse. As such, CEPP(B) may be considered for cytoreduction before ablative therapy and bone marrow transplantation. CEPP(B) may also be considered for initial therapy in selected patients who cannot tolerate doxorubicin-containing regimens. 0 1990 by The American Society of Hematology.
Computerized tomographic scans of the sites of disease and/or a lymphogram were done in the 80% of patients. All pathologic material was reviewed by members of the Stanford University Medical Center Pathology Department (Stanford, CA).
The CEPP(B) regimen (Table 1) consisted of cyclophosphamide 600 mg/m2 intravenously (IV) on days 1 and 8; VP-16 70 mg/m2 IV on days 1, 2, and 3; procarbazine 60 mg/m2 orally on days 1 through 10; prednisone 60 mg/m2 orally days 1 through 10; with or without bleomycin 15 U/m2 on days 1 and 15. Recently, we have begun to escalate the dose of cyclophosphamide by an additional 50 mg/m2 and VP-16 by 15 mg/m2 per monthly cycle if patients could tolerate this without complications of significant neutropenia. Current dose modification consists of 100% dose when the granulocyte count is greater than 1,500/mm3 and the platelet count is greater than 150,000. For a granulocyte count of 1,000 to 1,499 and a platelet count of 50,000 to 150,000,85% of the cyclophosphamide and VP-16 dose and 75% of the procarbazine dose is administered. Therapy is delayed 1 week for lower counts.
All treatment was given in the outpatient clinic. Tumor bulk was defined as any mass greater than 10 cm in greatest diameter. Tumor response was evaluated by monthly repeated physical examinations, chest x-rays, and abdominal films after lymphography. Selected radiologic studies and pathologic specimens were obtained when indicated to document response. A complete response (CR) was defined as the disappearance of all evidence of disease for at least 1 month. A decrease of 50% or greater of all disease sites for at least 1 month was defined as a partial response (PR). No response (NR) was defined as a less than 50% decrease in the tumor mass or tumor growth during therapy. Freedom from tumor progression and overall survival were calculated from the initiation of CEPP(B) therapy. Bleomycin was included in the drug regimen in 56 patients and excluded in 27 patients. Reasons for exclusion included prior treatment with bleomycin (9 patients), concern over an abnormal CXR (5), or prior significant smoking history and advanced age (1 3). Pulmonary function testing was not routinely performed. Prednisone was omitted in three patients previously treated with thoracic irradiation because of concerns of inducing radiation pneumonitis.
Chemotherapy.

From the Bone Marrow
Seventy-five of the 83 patients were evaluable for tumor response. Forty-one patients were treated with CEPP(B) after their first relapse, and 20 patients received this regimen following two or more prior relapses. The overall response rates in these two groups of patients with recurrent disease was not significantly different, as described in Table 3 . However, the incidence of obtaining a C R was less in patients after their second or subsequent relapse. A complete response was more likely to be achieved in patients who responded completely to their initial treatment. Patients who died early in the course of therapy were scored as treatment failures for Kaplan-Meier freedom from tumor progression and survival curves." Patient characteristics were compared using Fisher's Exact Test. The toxicity of therapy was evaluated for all patients. Oral mucosa was examined monthly as was assessment of nausea and vomiting. Patients were also questioned about any additional side effects. Six patients received concomitant or consolidative radiotherapy with CEPP(B).
RESULTS
Chemotherapy delivered and toxicity. The toxicity experienced by the patients is summarized in Table 2 . A total of 253 courses were administered to 83 patients. The median number of 28-day courses received was three (range 1 through 6). The most frequent side effect of CEPP(B) was myelosuppression. Eight patients required brief hospitalization for fever and neutropenia. None of these patients had a positive blood culture. Nausea and vomiting was judged to be severe in five patients, such that dose modification was required in three. Weakness and fatigue were recorded in two patients not requiring dose modification. Severe mucositis requiring dose reduction did not occur. Fatal toxicity occurred in one patient who developed the adult respiratory distress syndrome after the fourth cycle of CEPP(B). At this time, the patient had no evidence of lymphoma on physical or radiologic examination; transbronchial biopsy showed fibrosis only. Bleomycin or procarbazine was implicated in this patient's demise. Hemorrhagic cystitis developed after the fourth cycle of CEPP(B) in one patient who had been previously treated with cyclophosphamide. This resolved with discontinuation of the cyclophosphamide. A single patient developed a maculopapular rash that promptly disappeared with the discontinuation of procarbazine. One patient with low-grade lymphoma who had been treated previously with radiotherapy developed tumor lysis syndrome after the first course of CEPP(B) and had a rapid improvement with 4 days of dialysis. 
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relatively low incidence of achieving a CR consisted of the presence of systemic symptoms, tumor bulk greater than 10 cm, and a poor performance status. The exclusion of bleomycin from this regimen did not adversely affect the response rate. Table 4 outlines the characteristics and response rates in the 14 patients with diffuse large cell lymphoma who received CEPP(B) as primary therapy. The complete response rate in this group was 64%. Two of these patients had tumors that had undergone histologic transformation from a previous low-grade lymphoma. The median age was 72 years (range 40 to 82 years). When the youngest patient (a 40-year-old man who had received extensive radiotherapy and multiple chemotherapeutic regimens for recurrent testicular cancer) was excluded, all remaining patients were over the age of 65. The influence of patient characteristics on response rate was difficult to evaluate due the small numbers of patients.
The rate of tumor response according to histologic subtype is illustrated in Table 5 . For intermediate-grade lymphomas other than diffuse large cell, the ovefall response rate was 83%. For patients with recurrent diffuse large cell lymphoma, the overall response rate was 78%. Among patients with a histologic transformation from a low-grade to diffuse large cell lymphoma the overall response rate was 55%.
Overall, the percent CR in patients with recurrent intermediate-and high-grade lymphoma was 33%.
Freedom from progression data (Fig 1) indicates an ultimate poor prognosis Freedom from progression and survival. for patients who relapse after initial therapy for aggressive lymphomas. The median time to tumor progression is 7 months, and there is no indication of a cured population. However, 12 patients are surviving more than 2 years after initiation of CEPP(B) for recurrent lymphoma. The median survival for patients receiving CEPP(B) as second-line or subsequent therapy is 12 months, with 30% actuarial survival at 5 years (Fig 1) . 
DISCUSSION
Conventional chemotherapy for diffuse large cell lymphoma results in sustained complete remission such that the majority of patients are cured. However, those patients who do not achieve a CR or relapse subsequently have historically done very poorly. Therapeutic alternatives for patients who have failed doxorubicin-containing regimens include single agents, other combination chemotherapy, and autologous bone marrow transplantation for those patients who are eligible. There is no uniform second-line regimen that is considered optimal.
CEPP(B)
is an effective and well-tolerated regimen for the therapy of patients with relapsed intermediate-and highgrade lymphomas. Furthermore, it is useful in adult patients with aggressive lymphoma in whom doxorubicin may be medically contraindicated. This regimen is based on active drugs in the therapy of lymphoma, primarily VP-16. Our results compare favorably with other second-line regimens, some of which also include VP-16. Cabanillas et aI93'* reported a 62% response rate (CR, 37%; PR, 25%) with IMVP-16 (ifosfamide, methotrexate, VP 16) and a 60% response rate (CR, 24%; PR, 36%) with MIME (methyl-GAG, ifosfamide, methotrexate, VP 16) with equivalent toxicity. Our patient population is similar to those cited with the exception that patients receiving CEPP(B) had a higher percentage of prior CR. Furthermore, the response rates and There were no significant values of P < .05.
For 
TIME (YEARS)
survival data recorded with CEPP(B) appear similar to other non-VP-16 containing regimens such as the DHAP (cisplatin, cytosine arabinoside, dexamethasone) regimen reported by Velasquez et al," where the response rate is 58% (CR, 3 1 %; PR, 27%). The median survival using CEPP(B) for previously treated patients is 12 months. This result is comparable with combinations of etoposide, high-dose cytosine arabinoside, methylprednisolone, and cisplatin (ESHAP), with a reported median survival of 13 months, and DHAP, with a median survival of 7 months." Again, comparison of patient characteristics suggests that patients receiving CEPP(B) had a higher percentage of prior C R and perhaps less tumor bulk (although we defined bulk as a mass greater than 10 cm v 7 cm in DHAP patients). Other patient characteristics were similar in both patient groups. The CEPP(B) regimen also performs very well in another difficult group of patients; those with histologic transformation from a low-grade to a more aggressive histology. In this group there was an overall response rate of 55% (CR, 25%; PR, 30%). This response rate again compares favorably with previously reported experience by Armitage et alZo where only 1 of 9 patients treated with chemotherapy responded. Our CEPP(B) data are similar to our previously reported experience with histologic transformation at Stanford, where 6 of 17 (35%) patients achieved a C R using a variety of different therapeutic modalities." However, in our experience, these patients have an unfavorable prognosis for For personal use only. on April 13, 2017. by guest www.bloodjournal.org From survival when compared with patients with a de novo diagnosis of a diffuse large cell lymphoma. 22 An advantage of the CEPP(B) regimen is the ease of administration and low incidence of life-threatening complications and toxicity compared with other second-line regimens. As shown in Table 2 , only one patient died of treatment-related toxicity. All other toxicities were manageable with minimal morbidity. The regimen was modified especially for patients in whom bleomycin was medically contraindicated because of concern of added pulmonary toxicity to patients with pre-existing lung disease. The overall response of patients to this regimen without bleomycin (CEPP) does not appear to be significantly different.
In 14 previously untreated patients, CEPP(B) provided an encouraging response rate. Eight are alive and free of disease. In this group of patients, the median age was 72 years (range 40 to 82 years) and all had a cardiac contraindication for the use of doxorubicin. These results again compare favorably with other reported nondoxorubicincontaining regimens, such as COMLA, when used for the older age group with an overall response rate of 58% (CR, 33%; PR, 25%).23 However, these patients treated with COMLA had received prior curative radiotherapy or minimal chemotherapy.
The importance of age in the outcome of treatment for aggressive NHL has been controversial. A recent report from Vose et concludes that the responsiveness of aggressive NHL is not different in the older age group (260 years), but survival is decreased predominantly due to differences in cardiovascular events. The Vancouver group has reported the use of brief, weekly therapy with low-dose MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) or VABE (vincristine, doxorubicin, etoposide, bleomycin) in 66 elderly patients.25 The complete response rates were 66% and 57%, respectively. Only one third of patients receiving VABE were able to complete therapy, due to toxicity. Our results with the CEPP(B) regimen indicate that the majority of older patients respond favorably to this combination chemotherapy without excess morbidity and mortality. However, the numbers of patients in our series is quite small and the follow-up is relatively brief, indicating that further experience in this clinical setting is needed.
Recently, attention has been focused on the use of intensive chemoradiotherapy followed by autologous bone marrow transplant (ABMT) for recurrent lymphoma. However, ABMT is restricted to those younger in age (usually 560 years old) and good performance status. For those patients with disease that responds to conventional chemotherapy (responsive relapse), the group at the Dana Farber Cancer Center (Boston, MA) has presented encouraging results after achieving a "minimal disease state" and use of monoclonal antibody-purged marrow.26 Other groups have also shown the importance of a responsive relapse as a predictor of favorable outcome after ABMT.27 Although the ultimate freedom from progression data with CEPP(B) is similar to other reported regimens and equally sobering, the encouraging response rate together with mild toxicity makes CEPP(B) an appropriate regimen for initial cytoreduction before ablative therapy and ABMT. CEPP(B) can also be considered as a well-tolerated and effective palliative treatment for recurrent aggressive NHL. The doses of cyclophosphamide and, especially, VP-16 are modest; with the current dose escalation we hope to detect an improvement in freedom from progression without a significant increase in toxicity. Because the deletion of bleomycin did not seemingly affect the overall response rate, CEPP without bleomycin is being used at Stanford University Medical Center as the initial cytoreductive regimen for recurrent lymphoma before consolidation with ABMT.
